TABLE 4.
Drugs used along with daily dose and frequency of patients receiving each drug.
| Group | Drugs | Recommended dose (mg/kg of body weight) | Frequency of patients receiving each drug n (%) |
|---|---|---|---|
| Group 1 FLDs | H | 16–20 once daily (Max dose 1,500 mg) | 0 |
| E | 25 once daily (Max dose 2,000 mg) | 73 (26.9) | |
| Z | 30 to 40 | 269 (99.3) | |
| Group 2 injectable anti-TB drugs | Am | 15 to 20 | 249 (91.9) |
| Cm | 15 to 20 | 35 (12.9) | |
| Km | 15 to 20 | 0 | |
| S | 12–18 once daily (Max dose 1,000 mg) | 1 (0.4) | |
| Group 3 fluoroquinolones | Lfx | 7.5 to 10 | 241 (88.9) |
| Mfx | 7.5 to 10 | 33 (12.2) | |
| Group 4 oral bacteriostatic SLDs | Eto | 15 to 20 | 271 (100) |
| Pto | 15 to 20 | 0 | |
| Cs | 15 to 20 | 271 (100) | |
| PAS | 150 (Max dose 8–12 g) | 236 (87.1) | |
| Cfz | 100 mg once daily | 19 (7) | |
| Lzd | 600 my once daily | 19 (7) | |
| Bdq | 400 mg once daily for 2 weeks and then 200 mg three times per week | 1 (0.4) | |
| Group 5 anti-TB drugs with limited data available on the efficacy | Amx/Clv | 1,500/375 mg daily | 12 (4.4) |
| Clr | 1,000 mg once daily | 8 (3) |
H, isoniazid; E, ethambutol; Z, pyrazinamide; Cs, cycloserine; Eto, ethionamide; PAS, para-amino salicylic acid; Am, amikacin; Cm, capreomycin; Km, kanamycin; S, streptomycin; Lfx, levofloxacin; Mfx, moxifloxacin; Pto, prothionamide; Cfz, clofazimine; Bdq, bedaquiline; Amx, Amoxicillin; Clv, Clavolonate; Lzd, linezolid; Clr, clarithromycin.